Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Determine the Safety, Tolerability and Pharmacokinetics (PK) of IkT-148009 in Older Adult and Elderly Healthy Volunteers With Extension Into Parkinson's Patients

Next Previous
Trial Profile

A Phase I, Randomized Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Determine the Safety, Tolerability and Pharmacokinetics (PK) of IkT-148009 in Older Adult and Elderly Healthy Volunteers With Extension Into Parkinson's Patients

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risvodetinib (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Abliva; Inhibikase Therapeutics

Most Recent Events

  • 29 Jan 2024 According to an Inhibikase Therapeutics media release, data from a phase I, randomized, SAD, MAD, and PK study of risvodetinib in older adults and parkinsons disease were published in the peer reviewed Journal of Parkinsons Disease on January 13, 2024.
  • 29 Jan 2024 Results published in an Inhibikase Therapeutics Media Release.
  • 15 Feb 2023 According to an Inhibikase Therapeutics media release, company will present results from this trial at 11th Annual Alzheimer's & Parkinson's Drug Development Summit and the event is being held in San Francisco, California, on thurs Feb 23, 2023, 10:45am PT.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top